雄激素剥夺治疗抵抗性前列腺癌的治疗进展：进步的代价。
Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
机构信息
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
出版信息
Maturitas. 2011 Oct;70(2):194-6. doi: 10.1016/j.maturitas.2011.07.018. Epub 2011 Aug 9.
Abstract
Within the past two years, three agents have garnered approval from the US FDA for the specific treatment of metastatic castration resistant prostate cancer (mCRPC) - (1) abiraterone, (2) cabazitaxel and (3) sipuleucel-T. In separate phase III studies, each agent led to an improvement in overall survival (OS) of 2-4 months over a suitable comparator. With these costly therapies all having potential application in the patient with mCRPC, multiple entities (industry, government, and the general public) must strategize to determine how the cost burden of these agents can be balanced with the potential gains for the individual patient. Herein, we provide a framework with which to approach this dilemma.
摘要
在过去的两年中，有三种药物获得了美国 FDA 的批准，用于治疗转移性去势抵抗性前列腺癌（mCRPC）：（1）阿比特龙，（2）卡巴他赛，和（3）sipuleucel-T。在单独的 III 期研究中，每种药物与合适的对照药物相比，均使总生存期（OS）延长了 2-4 个月。由于这些昂贵的治疗方法都有可能应用于 mCRPC 患者，因此多个实体（行业、政府和公众）必须制定策略，以确定如何平衡这些药物的成本负担与个体患者的潜在获益。在此，我们提供了一种方法来解决这个难题。
相似文献
1
Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.雄激素剥夺治疗抵抗性前列腺癌的治疗进展：进步的代价。
Maturitas. 2011 Oct;70(2):194-6. doi: 10.1016/j.maturitas.2011.07.018. Epub 2011 Aug 9.
2
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.阿比特龙在不断演变的去势抵抗性前列腺癌治疗格局中的 III 期数据。
Maturitas. 2011 Feb;68(2):103-5. doi: 10.1016/j.maturitas.2010.10.009. Epub 2010 Nov 19.
3
New treatment options for castration-resistant prostate cancer.去势抵抗性前列腺癌的新治疗选择。
Am J Health Syst Pharm. 2013 May 15;70(10):856-65. doi: 10.2146/ajhp110586.
4
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.优化英国晚期前列腺癌患者的护理：当前的挑战和未来的机会。
BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19.
5
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌的当前范式和不断发展的概念。
Asian J Androl. 2011 Sep;13(5):683-9. doi: 10.1038/aja.2011.35. Epub 2011 May 23.
6
Castration-resistant prostate cancer: systemic therapy in 2012.去势抵抗性前列腺癌：2012 年的系统治疗。
Clinics (Sao Paulo). 2012;67(4):389-94. doi: 10.6061/clinics/2012(04)13.
7
New agents in the arsenal to fight castrate-resistant prostate cancer.新武器助力攻克去势抵抗性前列腺癌。
Curr Oncol Rep. 2013 Jun;15(3):239-48. doi: 10.1007/s11912-013-0305-9.
8
Castration refractory prostate cancer: cinderella finally comes to the ball.去势抵抗性前列腺癌：灰姑娘终于步入舞会。
Onkologie. 2010;33(12):655-6. doi: 10.1159/000322635. Epub 2010 Nov 29.
9
Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.采用醋酸阿比特龙加泼尼松治疗转移性去势抵抗性前列腺癌患者对美国一项医保计划的预算影响。
J Manag Care Pharm. 2013 Nov-Dec;19(9):799-808. doi: 10.18553/jmcp.2013.19.9.799.
10
New treatment options for patients with metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌患者的新治疗选择。
Cancer Treat Rev. 2012 Aug;38(5):340-5. doi: 10.1016/j.ctrv.2011.07.007. Epub 2011 Sep 23.
引用本文的文献
1
The Efficacy of Cabazitaxel in Treating Prostate Cancer: A Systematic Review and Meta-Analysis.卡巴他赛治疗前列腺癌的疗效：系统评价和荟萃分析。
Am J Mens Health. 2024 Sep-Oct;18(5):15579883241285162. doi: 10.1177/15579883241285162.
2
Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database.巴西晚期前列腺癌患者的治疗模式：一项私立医疗保健系统数据库分析
World J Oncol. 2022 Dec;13(6):350-358. doi: 10.14740/wjon1476. Epub 2022 Dec 24.
3
Biological Products: Cellular Therapy and FDA Approved Products.生物制品：细胞治疗和 FDA 批准产品。
Stem Cell Rev Rep. 2019 Apr;15(2):166-175. doi: 10.1007/s12015-018-9866-1.
4
Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.治疗性癌症疫苗与免疫疗法的经济学评估：一项系统综述
Hum Vaccin Immunother. 2014;10(11):3415-24. doi: 10.4161/hv.29407.
5
A new age for vaccine therapy in renal cell carcinoma.肾细胞癌疫苗治疗的新时代。
Cancer J. 2013 Jul-Aug;19(4):365-70. doi: 10.1097/PPO.0b013e31829d74b4.
本文引用的文献
1
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.随机、双盲、安慰剂对照 III 期临床试验比较多西他赛和泼尼松与或不与贝伐珠单抗在转移性去势抵抗性前列腺癌男性患者中的疗效：CALGB 90401。
J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.
2
Expanding treatment options for metastatic prostate cancer.扩大转移性前列腺癌的治疗选择。
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
3
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
4
Listening to Provenge--what a costly cancer treatment says about future Medicare policy.聆听“普罗文奇”——一种昂贵的癌症治疗方法对未来医疗保险政策的启示。
N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.
5
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.用于去势抵抗性前列腺癌的西妥昔单抗-T免疫疗法。
N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982.
6
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
7
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
8
Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.钐 Sm-153 乙膦二钠重复给药对转移性骨痛患者的安全性和有效性。
Cancer. 2007 Feb 1;109(3):637-43. doi: 10.1002/cncr.22431.
9
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.多西他赛与雌莫司汀对比米托蒽醌和泼尼松治疗晚期难治性前列腺癌的疗效
N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.
10
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗
N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.
Zotero 插件